JPMorgan Issues Buy Recommendation for AbbVie with $260 Target Price

JPMorgan Global Markets has issued a buy recommendation for AbbVie (ABBV) and set a price target of $260. Analysts note that while competitive concerns may constrain the company’s growth potential, a robust drug pipeline and patent protection can offset these risks. In its fundamental analysis, JPMorgan highlighted AbbVie’s biopharmaceutical portfolio and the sustainability of its new drug development process as drivers of long‑term growth. Rising competition—particularly from generic manufacturers and emerging biotech firms—is identified as a significant risk. However, the company’s pricing strategy and strong financial performance are seen as capable of mitigating competitive pressures. The report also emphasized AbbVie’s plans to expand its portfolio through mergers and acquisitions, which are expected to support the company’s long‑term growth objectives. Nonetheless, regulatory changes, patent expirations, and medical research costs remain key risk factors. Investors are advised to consider their risk tolerance and portfolio balance when evaluating JPMorgan’s buy recommendation. The recommendation offers a balanced view of potential returns and risks in light of market conditions and the company’s financial metrics. This is not investment advice.